On January 7, 2019, Nicholas J. Sarlis, informed SELLAS Life Sciences Group, Inc. of his intention, for personal reasons, to resign as Executive Vice President and Chief Medical Officer of the company, effective the earlier of May 15, 2019 or the appointment of his successor. Dr. Michael Kurman, clinical consultant to the Company, will continue to oversee the Company’s clinical operations and will undertake additional responsibilities in respect to clinical development. He is a board-certified medical oncologist and, during his career in the pharmaceutical industry, has held positions of progressive responsibility at Janssen Pharmaceuticals as Director of Oncology, Cytogen Corporation as Senior Director of Research, and U.S. Bioscience as Vice-President for Research. Dr. Kurman also served as Vice-President for Clinical and Scientific Operations for Quintiles’ Oncology Therapeutics Division.